Michael Altmann
About Michael Altmann
Michael Altmann is the Access & Value Strategy Manager Immunology & Fibrosis at Bristol Myers Squibb in München, Bayern, Deutschland. He has extensive experience in market access roles and a strong academic background in health economics and management.
Current Company and Role
Michael Altmann is currently employed at Bristol Myers Squibb as an Access & Value Strategy Manager specializing in Immunology & Fibrosis. He operates out of München, Bayern, Deutschland, where his role likely involves strategizing for market access and establishing value propositions for products within the Immunology & Fibrosis portfolio.
Previous Positions at Bristol Myers Squibb
Michael Altmann has held various roles at Bristol Myers Squibb. From 2021 to 2022, he was an Access & Payer Strategy Manager for Immunology & Fibrosis. Prior to this, he served as a Junior Access Manager for Immunoscience & Precision Medicine from 2019 to 2020. He also gained experience as a Werkstudent Market Access from 2017 to 2019 and was a Praktikant Market Access for 5 months in 2017.
Market Access Experience at Novartis
In 2017, Michael Altmann worked at Novartis in Basel, Switzerland, as a Praktikant focusing on Market Access, Pricing & Reimbursement. Although his tenure was relatively short, his role likely provided him with foundational knowledge and experience that he has carried forward into his subsequent positions.
Early Career at IMS Health
From 2015 to 2017, Michael Altmann worked as a Werkstudent in Health Economics & Outcomes Research at IMS Health in München, Bayern, Deutschland. His role involved contributing to research and analysis in the field of health economics, which has underpinned his later career moves in market access and payer strategy roles.
Education in Health Economics and Management
Michael Altmann has a robust academic background in health economics and management. He earned a Master of Science degree in Gesundheitsmanagement & -ökonomie from Friedrich-Alexander-Universität Erlangen-Nürnberg in 2019. Prior to that, he obtained a Bachelor of Arts in Gesundheitsökonomie from Hochschule Fresenius in 2017 and studied Betriebswirtschaftslehre at Ludwig-Maximilians Universität München from 2011 to 2014.